Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCRT, CAPEOX, and Serplulimab in MSS/pMMR Rectal Cancer With Synchronous Oligometastases
NCT06850103Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab in rectal cancer, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Started Apr 2025; status: recruiting.
02
Drugs
serplulimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06850103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06850103.